297 related articles for article (PubMed ID: 18604652)
21. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
Gerardy J
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: stimulation of 5-HT2 receptors induces malignant hyperthermia.
Löscher W; Witte U; Fredow G; Ganter M; Bickhardt K
Naunyn Schmiedebergs Arch Pharmacol; 1990 Jun; 341(6):483-93. PubMed ID: 2118235
[TBL] [Abstract][Full Text] [Related]
23. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca.
McKenna DJ; Towers GH; Abbott F
J Ethnopharmacol; 1984 Apr; 10(2):195-223. PubMed ID: 6587171
[TBL] [Abstract][Full Text] [Related]
24. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
Lamensdorf I; Youdim MB; Finberg JP
J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
[TBL] [Abstract][Full Text] [Related]
25. The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs.
Riga MS; Soria G; Tudela R; Artigas F; Celada P
Int J Neuropsychopharmacol; 2014 Aug; 17(8):1269-82. PubMed ID: 24650558
[TBL] [Abstract][Full Text] [Related]
26. Behavioural hyperactivity in rats treated with selective monoamine oxidase inhibitors and LM 5008, a selective 5-hydroxytryptamine uptake blocker.
Ashkenazi R; Finberg JP; Youdim MB
Br J Pharmacol; 1983 Jul; 79(3):765-70. PubMed ID: 6418248
[TBL] [Abstract][Full Text] [Related]
27. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
Riba J; McIlhenny EH; Valle M; Bouso JC; Barker SA
Drug Test Anal; 2012; 4(7-8):610-6. PubMed ID: 22514127
[TBL] [Abstract][Full Text] [Related]
28. Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats.
Kitaichi Y; Inoue T; Nakagawa S; Izumi T; Koyama T
Eur J Pharmacol; 2006 Feb; 532(3):236-45. PubMed ID: 16487506
[TBL] [Abstract][Full Text] [Related]
29. Gestational exposure to nicotine and monoamine oxidase inhibitors influences cocaine-induced locomotion in adolescent rats.
Franke RM; Belluzzi JD; Leslie FM
Psychopharmacology (Berl); 2007 Nov; 195(1):117-24. PubMed ID: 17653695
[TBL] [Abstract][Full Text] [Related]
30. Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area.
Chenu F; El Mansari M; Blier P
Int J Neuropsychopharmacol; 2009 May; 12(4):475-85. PubMed ID: 18700056
[TBL] [Abstract][Full Text] [Related]
31. Abuse liability profile of three substituted tryptamines.
Gatch MB; Forster MJ; Janowsky A; Eshleman AJ
J Pharmacol Exp Ther; 2011 Jul; 338(1):280-9. PubMed ID: 21474568
[TBL] [Abstract][Full Text] [Related]
32. Subthalamic 5-HT(1A) and 5-HT(1B) receptor modulation of RU 24969-induced behavioral profile in rats.
Martinez-Price DL; Geyer MA
Pharmacol Biochem Behav; 2002 Apr; 71(4):569-80. PubMed ID: 11888548
[TBL] [Abstract][Full Text] [Related]
33. Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT(1A) receptor knockout mice: implications for schizophrenia.
van den Buuse M; Ruimschotel E; Martin S; Risbrough VB; Halberstadt AL
Neuropharmacology; 2011; 61(1-2):209-16. PubMed ID: 21501627
[TBL] [Abstract][Full Text] [Related]
34. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.
Davis AK; Barsuglia JP; Lancelotta R; Grant RM; Renn E
J Psychopharmacol; 2018 Jul; 32(7):779-792. PubMed ID: 29708042
[TBL] [Abstract][Full Text] [Related]
35. The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.
Sagi Y; Driguès N; Youdim MB
Br J Pharmacol; 2005 Oct; 146(4):553-60. PubMed ID: 16086033
[TBL] [Abstract][Full Text] [Related]
36. Altered behavior and alcohol tolerance in transgenic mice lacking MAO A: a comparison with effects of MAO A inhibitor clorgyline.
Popova NK; Vishnivetskaya GB; Ivanova EA; Skrinskaya JA; Seif I
Pharmacol Biochem Behav; 2000 Dec; 67(4):719-27. PubMed ID: 11166062
[TBL] [Abstract][Full Text] [Related]
37. Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids
Brito-da-Costa AM; Dias-da-Silva D; Gomes NGM; Dinis-Oliveira RJ; Madureira-Carvalho Á
Pharmaceuticals (Basel); 2020 Oct; 13(11):. PubMed ID: 33114119
[TBL] [Abstract][Full Text] [Related]
38. A switch mechanism between locomotion and mouthing implicated in sensitization to quinpirole in rats.
Culver KE; Rosenfeld JM; Szechtman H
Psychopharmacology (Berl); 2000 Aug; 151(2-3):202-10. PubMed ID: 10972466
[TBL] [Abstract][Full Text] [Related]
39. Interactive effects of mGlu5 and 5-HT2A receptors on locomotor activity in mice.
Halberstadt AL; Lehmann-Masten VD; Geyer MA; Powell SB
Psychopharmacology (Berl); 2011 May; 215(1):81-92. PubMed ID: 21153406
[TBL] [Abstract][Full Text] [Related]
40. Short-term erythrosine B-induced inhibition of the brain regional serotonergic activity suppresses motor activity (exploratory behavior) of young adult mammals.
Dalal A; Poddar MK
Pharmacol Biochem Behav; 2009 Jun; 92(4):574-82. PubMed ID: 19264092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
